Patents Examined by Shobha Kantamneni
  • Patent number: 10765642
    Abstract: The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: September 8, 2020
    Assignees: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Ki Sun Kwon, Jeongi Choi, Sung Sup Park, Sun Gun Chung, Eun Soo Kwon, Kwang-Pyo Lee, Seung Min Lee
  • Patent number: 10722584
    Abstract: The present invention relates generally to the field of flavan-3-ols. In particular, the present invention provides a way to increase the bioavailability of flavan-3-ols. Embodiments of the present invention relate to the use of at least one polyphenolic compound in a composition comprising at least one flavan-3-ol for increasing the bioavailability of said flavan-3-ol, wherein the at least one polyphenolic compound is selected from a group consisting of flavonols, flavones, isoflavones, flavanones, or combinations thereof.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: July 28, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Lucas Actis Goretta, Antoine Leveques, Marcia Da Silva Pinto, Magalie Sabatier, Maarit Rein, Gary Williamson, Fabiola Dionisi
  • Patent number: 10675255
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 9, 2020
    Assignee: Enzo Bochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan
  • Patent number: 10668157
    Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 2, 2020
    Assignees: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.
    Inventors: Haruka Obata, Kiyoshi Shoji, Yoshiko Yamazaki, Toru Matsunaga, Takao Sato, Wakiko Asayama, Shinichi Yasueda
  • Patent number: 10668046
    Abstract: Provided herein are compositions comprising a stable water-in-silicone emulsion, and methods and kits comprising the compositions for treating conditions.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 2, 2020
    Assignee: Ansella Therapeutics, Inc.
    Inventor: Jason M. Criscione
  • Patent number: 10660879
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: May 26, 2020
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan, Paul Diamond
  • Patent number: 10653702
    Abstract: The invention relates to the field of metal-organic framework materials and the field of medical technology, relates to a method for inhibiting tumor angiogenesis or preventing and/or treating tumor, comprising administering to a subject in need thereof an effective amount of a metal-organic framework comprising Fe and ligand. The invention further relates to a method for inhibiting the expression of matrix metalloproteinase in a cell, comprising administering to the cell an effective amount of a metal-organic framework comprising Fe and ligand.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 19, 2020
    Assignee: Yunnan University
    Inventors: Bin Li, Daomei Chen, Jiaqiang Wang, Minfang Nie
  • Patent number: 10646427
    Abstract: This invention concerns a cosmetic composition comprising, in a physiologically acceptable medium, an aqueous phase, spiculisporic acid and/or one of its salts, and at least one ester of fatty acid and optionally polyoxyalkylenated (poly)glycerol. This invention further concerns the non-therapeutic, cosmetic use of the cosmetic composition as a hygienic product, makeup, a cleaning product, and/or care product of the skin and/or hair.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 12, 2020
    Assignee: L'OREAL
    Inventors: Caroline Sirichandra, Isabelle Terrisse, Géraldine Lerebour
  • Patent number: 10624896
    Abstract: The present invention refers to the use of sodium channel blockers such as tetrodotoxin or saxitoxin, its analogues/derivatives as well as their acceptable salts, for the production of a medicament for the treatment of neuropathic pain resulting from chemotherapy.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 21, 2020
    Assignee: Wex Medical Limited
    Inventors: Helmut Heinrich Buschmann, Jose Miguel Vela Hernandez, Jose Manuel Baeyens
  • Patent number: 10624869
    Abstract: Methods for the treatment of cancer, including glioblastoma multiforme (GBM) and recurrent glioblastoma multiforme (RGBM). The method includes administering to a patient a plurality of extraneous antineoplastons and a plurality of targeted agents. The plurality of extraneous antineoplastons may include two or more antineoplastons selected from phenylacetylglutaminate sodium (PG), phenylacetylisoglutaminate sodium (iso-PG), and phenylacetate (PN). The plurality of targeted agents may include two or more agents selected from bevacizumab, pazopanib, sorafenib, dasatinib, and everolimus.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: April 21, 2020
    Inventor: Stanislaw R. Burzynski
  • Patent number: 10589002
    Abstract: Provided are novel biocompatible copolymers, compositions comprising the copolymers, and methods of using the copolymers. The copolymers are non-toxic and typically have an LCST below 37° C. Compositions comprising the copolymers can be used for wound treatment, as a cellular growth matrix or niche and for injection into cardiac tissue to repair and mechanically support damaged tissue. The copolymers comprise numerous ester linkages so that the copolymers are erodeable in situ. Degradation products of the copolymers are soluble and non-toxic. The copolymers can be amine-reactive so that they can conjugate with proteins, such as collagen. Active ingredients, such as drugs, can be incorporated into compositions comprising the copolymers.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: March 17, 2020
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Hongbin Jiang, William R. Wagner, Tomo Yoshizumi, Yang Zhu
  • Patent number: 10583103
    Abstract: Described herein are inventions directed to methods of treating a diastolic cardiac dysfunction and the symptoms thereof in a subject that includes administering an amount of a TRPV2 receptor agonist effective to treat the diastolic cardiac dysfunction. The TRPV2 receptor agonist may be administered in at least one of an injection, orally, or transdermally. The amount of TRPV2 receptor agonist is sufficient to result in an improved performance on quantitative diagnostic criteria. In an embodiment, the TRPV2 receptor agonist is administered over a period of about 8 hours to about 24 hours. The TRPV2 receptor agonist may be used for short term treatments, i.e., less than a week, or it may be administered in a long term manner, i.e., over a period of weeks, months, or even years. Exemplary TRPV2 receptor agonists include probenecid, 2-aminoethoxydiphenyl borate, cannabinol, cannabidiol, and combinations thereof.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: March 10, 2020
    Assignee: University of Cincinnati
    Inventors: Jack Rubinstein, W. Keith Jones
  • Patent number: 10583081
    Abstract: A kit that is made of an apparatus comprising a bottle and a nozzle sprayer, and a pharmaceutical formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder. A method for treating mouth ulcers comprising administering to a patient a formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder to an affected area.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: March 10, 2020
    Inventor: Richard A. Myers
  • Patent number: 10562901
    Abstract: A temozolomide compound according to formula (I) is described, wherein R1, L1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: February 18, 2020
    Assignee: THE UNIVERSITY OF MASSACHUSETTS
    Inventors: Todd Emrick, Matthew Skinner, Sarah M. Ward, Banishree Saha
  • Patent number: 10507207
    Abstract: The invention refers to the use of Reverse Transcriptase (RT) inhibitor compounds for the preparation of pharmaceutical compositions to counteract the loss of cellular differentiation in tumour and non tumour pathologies, said compound being able to bind the hydrophobic pocket on the RT subunit p66. Particularly preferred for such uses are the following compounds: nevirapine, efavirenz, delavirdine, corresponding salts and/or pharmaceutically acceptable derivatives thereof.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: December 17, 2019
    Assignee: ISTITUTO SUPERIORE DI SANITA
    Inventors: Corrado Spadafora, Patriźia Ĺavia, Elisabetta Mattei, Gugliemo Palombini, Rodolfo Nello Lorenzini, Clara Nervi
  • Patent number: 10507208
    Abstract: Compositions, packaged pharmaceuticals, and methods of treatment by the sensitization of resistant tumors are provided. The compositions comprise a combination of a hedgehog pathway modulator, such as itraconazole, and a chemotherapeutic agent. Tumor cells in mammalian subjects treated with the hedgehog pathway modulator are sensitized to the effects of the chemotherapeutic agent, thus increasing the therapeutic index of the agent and reducing toxicity to the subject.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: December 17, 2019
    Inventor: Vikash J. Bhagwandin
  • Patent number: 10500173
    Abstract: Antimicrobial silicone-based dressings, such as wound dressings, are disclosed. An example dressing comprises a transparent and self-adhesive gel sheet cured from a liquid containing silicone, the sheet having dispersed therein (i) particulates of a chlorhexidine compound that is not soluble in the liquid; and (ii) at least one other antimicrobial. Methods of making the silicone-based dressings and methods of use are also disclosed.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: December 10, 2019
    Assignee: COVALON TECHNOLOGIES INC.
    Inventors: Liu Yang, Valerio DiTizio
  • Patent number: 10478441
    Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 19, 2019
    Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
    Inventors: Berten Ceulemens, Lieven Lagae
  • Patent number: 10478442
    Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: November 19, 2019
    Assignees: THE KATHOLIEKE UNIVERSITEIT LEUVEN, UNIVERSITY HOSPITAL ANTWERP
    Inventors: Berten Ceulemens, Lieven Lagae
  • Patent number: 10470992
    Abstract: The invention relates to a composition comprising 2% to 5% minoxidil, 0.01% to 15% finasteride and 0.01% to 15% of a prostaglandin analog. In one embodiment, the prostaglandin analog is latanoprost. I a preferred embodiment, the composition comprises 5% minoxidil, 0.1% finasteride and 0.03% latanoprost. The invention also relates to the use of the said composition to reduce hair loss and/or increase regrowth of hair in a human subject.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: November 12, 2019
    Assignee: Triple Hair Inc.
    Inventor: Houfar Sekhavat